Journal Article
. 2005 Jul;23(22).
doi: 10.1200/JCO.2005.09.423.

Randomized trial comparing cyclophosphamide, epirubicin, and fluorouracil with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer: update of National Cancer Institute of Canada Clinical Trials Group Trial MA5

Mark N Levine 1 Kathleen I Pritchard  Vivien H C Bramwell  Lois E Shepherd  Dongsheng Tu  Nancy Paul  National Cancer Institute of Canada Clinical Trials Group  
Affiliations
  • PMID: 16051958
  •     46 citations

Abstract

Purpose: Certain anthracycline-containing adjuvant chemotherapy regimens are associated with improved relapse-free survival (RFS) and overall survival (OS) compared with the classic regimen of cyclophosphamide, methotrexate, and fluorouracil in women with early-stage breast cancer.

Patients And Methods: Between 1989 and 1993, 710 pre- and perimenopausal women with axillary node-positive breast cancer were randomly assigned to either cyclophosphamide 75 mg/m(2) orally days 1 through 14, epirubicin 60 mg/m(2) intravenously days 1 and 8, and fluorouracil 500 mg/m(2) intravenously days 1 and 8 (CEF) or CMF (cyclophosphamide 100 mg/m(2) orally days 1 through 14, methotrexate 40 mg/m(2) intravenously days 1 and 8, and fluorouracil 600 mg/m(2) intravenously days 1 and 8). On the basis of follow-up to May 1997 (median follow-up time, 59 months), there was a statistically significant improvement in RFS and OS for CEF compared with CMF.

Results: The trial results are now updated, with a median follow-up of 10 years for live patients. The 10-year RFS is 52% for patients who received CEF compared with 45% for CMF patients (hazard ratio [HR] for CMF v CEF = 1.31; stratified log-rank, P = .007). The 10-year OS for patients who received CEF and CMF are 62% and 58%, respectively (HR for CMF v CEF = 1.18; stratified log-rank, P = .085). The rates of acute leukemia have not changed since the original report, whereas the rates of congestive heart failure are slightly higher but acceptable (four patients [1.1%] in the CEF group v one patient [0.3%] in the CMF group).

Conclusion: The previously demonstrated benefit of CEF compared with CMF adjuvant chemotherapy is maintained with longer follow-up in the MA5 trial.

Does timing of adjuvant chemotherapy influence the prognosis after early breast cancer?
C Alliot.
Br J Cancer, 2006 Mar 09; 94(6). PMID: 16523197    Free PMC article.
The role of trastuzumab in early stage breast cancer: current data and treatment recommendations.
Amy Lin, Hope S Rugo.
Curr Treat Options Oncol, 2007 Jul 31; 8(1). PMID: 17660958
Review.
Anemia is a common but neglected complication of adjuvant chemotherapy for early breast cancer.
A Goldrick, I A Olivotto, +4 authors, P T Truong.
Curr Oncol, 2007 Dec 15; 14(6). PMID: 18080014    Free PMC article.
tAnGo: a randomised phase III trial of gemcitabine in paclitaxel-containing, epirubicin/cyclophosphamide-based, adjuvant chemotherapy for early breast cancer: a prospective pulmonary, cardiac and hepatic function evaluation.
A M Wardley, L Hiller, +8 authors, tAnGo Trial Collaborators.
Br J Cancer, 2008 Jul 31; 99(4). PMID: 18665163    Free PMC article.
Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy.
F P O'Malley, S Chia, +5 authors, K I Pritchard.
J Natl Cancer Inst, 2009 Apr 30; 101(9). PMID: 19401546    Free PMC article.
Outcome of patients with early-stage breast cancer treated with doxorubicin-based adjuvant chemotherapy as a function of HER2 and TOP2A status.
Raymond Tubbs, William E Barlow, +11 authors, Daniel F Hayes.
J Clin Oncol, 2009 Jul 22; 27(24). PMID: 19620488    Free PMC article.
Taxanes: optimizing adjuvant chemotherapy for early-stage breast cancer.
Philippe L Bedard, Angelo Di Leo, Martine J Piccart-Gebhart.
Nat Rev Clin Oncol, 2009 Dec 10; 7(1). PMID: 19997076
Review.
Topoisomerase IIalpha expression rather than gene amplification predicts responsiveness of adjuvant anthracycline-based chemotherapy in women with primary breast cancer.
Christian Schindlbeck, D Mayr, +7 authors, K Friese.
J Cancer Res Clin Oncol, 2010 Jan 07; 136(7). PMID: 20052594
Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials.
Lesley A Smith, Victoria R Cornelius, +4 authors, Alison Jones.
BMC Cancer, 2010 Jul 01; 10. PMID: 20587042    Free PMC article.
Highly Cited. Systematic Review.
A feasibility study of bevacizumab plus dose-dense doxorubicin-cyclophosphamide (AC) followed by nanoparticle albumin-bound paclitaxel in early-stage breast cancer.
Heather L McArthur, Hope Rugo, +30 authors, Maura N Dickler.
Clin Cancer Res, 2011 Feb 26; 17(10). PMID: 21350003    Free PMC article.
Efficacy of taxanes as adjuvant treatment of breast cancer: a review and meta-analysis of randomised clinical trials.
Jordi Ginés, Eliazar Sabater, +3 authors, Miguel A Casado.
Clin Transl Oncol, 2011 Jul 22; 13(7). PMID: 21775276
Review.
Comparison of CVF (Cyclophosphamide+Vinorelbine+5-Fluorouracil) and CMF (Cyclophosphamide+Methotrexate+5-Fluorouracil) Adjuvant Chemotherapy in Early Breast Cancer.
Geumhee Gwak, Kyeongmee Park, +10 authors, Sung-Jin Park.
J Breast Cancer, 2011 Oct 28; 14(3). PMID: 22031805    Free PMC article.
Impact of a reduced dose intensity of adjuvant anthracycline based chemotherapy in a population-based cohort of stage I-II breast cancers.
A V Tinker, C Speers, +2 authors, S Chia.
Ecancermedicalscience, 2008 Jan 01; 2. PMID: 22275960    Free PMC article.
Responsiveness of intrinsic subtypes to adjuvant anthracycline substitution in the NCIC.CTG MA.5 randomized trial.
Maggie C U Cheang, K David Voduc, +15 authors, Torsten O Nielsen.
Clin Cancer Res, 2012 Feb 22; 18(8). PMID: 22351696    Free PMC article.
A multicenter phase II study of TSU-68, a novel oral multiple tyrosine kinase inhibitor, in patients with metastatic breast cancer progressing despite prior treatment with an anthracycline-containing regimen and taxane.
Yasuhiro Suzuki, Toshiaki Saeki, +10 authors, Yutaka Tokuda.
Int J Clin Oncol, 2012 May 16; 18(4). PMID: 22585426
Why does Oncotype DX recurrence score reduce adjuvant chemotherapy use?
Jeffrey G Schneider, Danny N Khalil.
Breast Cancer Res Treat, 2012 Jun 23; 134(3). PMID: 22723033    Free PMC article.
Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study.
Erin J Aiello Bowles, Robert Wellman, +13 authors, Pharmacovigilance Study Team.
J Natl Cancer Inst, 2012 Sep 06; 104(17). PMID: 22949432    Free PMC article.
Highly Cited.
Thymoquinone attenuates cyclophosphamide-induced pulmonary injury in rats.
Ghada M Suddek, Nora A Ashry, Nariman M Gameil.
Inflammopharmacology, 2012 Dec 01; 21(6). PMID: 23196752
Molecular characterization of basal-like and non-basal-like triple-negative breast cancer.
Aleix Prat, Barbara Adamo, +3 authors, Charles M Perou.
Oncologist, 2013 Feb 14; 18(2). PMID: 23404817    Free PMC article.
Highly Cited. Review.
Cardiac toxicity of anticancer agents.
Alessandro Colombo, Carlo Cipolla, Marta Beggiato, Daniela Cardinale.
Curr Cardiol Rep, 2013 Mar 21; 15(5). PMID: 23512625
Review.
Is TIMP-1 immunoreactivity alone or in combination with other markers a predictor of benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial?
Alison F Munro, Annette Bartels, +4 authors, John M S Bartlett.
Breast Cancer Res, 2013 Apr 11; 15(2). PMID: 23570501    Free PMC article.
Common variants in genes coding for chemotherapy metabolizing enzymes, transporters, and targets: a case-control study of contralateral breast cancer risk in the WECARE Study.
Jennifer D Brooks, Sharon N Teraoka, +11 authors, Jane C Figueiredo.
Cancer Causes Control, 2013 Jun 19; 24(8). PMID: 23775025    Free PMC article.
Toxicity Analysis in the ADEBAR Trial: Sequential Anthracycline-Taxane Therapy Compared with FEC120 for the Adjuvant Treatment of High-Risk Breast Cancer.
Alexandra Schönherr, Viktoria Aivazova-Fuchs, +14 authors, Brigitte Rack.
Breast Care (Basel), 2013 Aug 02; 7(4). PMID: 23904831    Free PMC article.
Side effects of standard adjuvant and neoadjuvant chemotherapy regimens according to age groups in primary breast cancer.
Mattea Reinisch, Gunter von Minckwitz, +6 authors, Sibylle Loibl.
Breast Care (Basel), 2014 Apr 10; 8(1). PMID: 24715845    Free PMC article.
Adjuvant chemotherapy in breast cancer: To use or not to use, the anthracyclines.
Jennifer A Crozier, Abhisek Swaika, Alvaro Moreno-Aspitia.
World J Clin Oncol, 2014 Aug 13; 5(3). PMID: 25114866    Free PMC article.
Review.
Chemotherapy in early breast cancer: when, how and which one?
Marcus Schmidt.
Breast Care (Basel), 2014 Sep 02; 9(3). PMID: 25177256    Free PMC article.
Review.
Standard of care and promising new agents for triple negative metastatic breast cancer.
Patrizia Mancini, Antonio Angeloni, +2 authors, Silvia Mezi.
Cancers (Basel), 2014 Oct 28; 6(4). PMID: 25347122    Free PMC article.
Review.
Breast cancer survivorship: a comprehensive review of long-term medical issues and lifestyle recommendations.
Balazs I Bodai, Phillip Tuso.
Perm J, 2015 Apr 23; 19(2). PMID: 25902343    Free PMC article.
Review.
Defining breast cancer intrinsic subtypes by quantitative receptor expression.
Maggie C U Cheang, Miguel Martin, +21 authors, Lisa A Carey.
Oncologist, 2015 Apr 25; 20(5). PMID: 25908555    Free PMC article.
Adjuvant Metronomic CMF in a Contemporary Breast Cancer Cohort: What's Old Is New.
Eunpi Cho, Ann K Schwemm, +7 authors, Vijayakrishna K Gadi.
Clin Breast Cancer, 2015 May 31; 15(5). PMID: 26025883    Free PMC article.
Triple negative breast cancer: looking for the missing link between biology and treatments.
Giuseppe Palma, Giuseppe Frasci, +7 authors, Massimiliano D'Aiuto.
Oncotarget, 2015 Sep 21; 6(29). PMID: 26387133    Free PMC article.
Highly Cited. Review.
Effectiveness of an Adjuvant Chemotherapy Regimen for Early-Stage Breast Cancer: A Systematic Review and Network Meta-analysis.
Takeo Fujii, Fanny Le Du, +6 authors, Naoto T Ueno.
JAMA Oncol, 2015 Sep 25; 1(9). PMID: 26402167    Free PMC article.
Systematic Review.
Jointly modeling longitudinal proportional data and survival times with an application to the quality of life data in a breast cancer trial.
Hui Song, Yingwei Peng, Dongsheng Tu.
Lifetime Data Anal, 2015 Sep 26; 23(2). PMID: 26403909
Clinical significance of locoregional and systemic treatment in operable high-risk breast cancer patients with more than four positive axillary lymph nodes.
Kai Yin, Liheng Zhou, +2 authors, Jinsong Lu.
Onco Targets Ther, 2015 Oct 08; 8. PMID: 26442757    Free PMC article.
Exploring circulating micro-RNA in the neoadjuvant treatment of breast cancer.
Máire-Caitlín Casey, Karl J Sweeney, James Andrew Lawrence Brown, Michael J Kerin.
Int J Cancer, 2016 Jan 13; 139(1). PMID: 26756433    Free PMC article.
Review.
Adjuvant Dose-Dense Chemotherapy in Breast Cancer: Standard of Care in High-Risk Patients.
Volker Möbus.
Breast Care (Basel), 2016 Apr 07; 11(1). PMID: 27051389    Free PMC article.
Review.
Improved systemic treatment for early breast cancer improves cure rates, modifies metastatic pattern and shortens post-metastatic survival: 35-year results from the Munich Cancer Registry.
Dieter Hölzel, Renate Eckel, +11 authors, Jutta Engel.
J Cancer Res Clin Oncol, 2017 Apr 22; 143(9). PMID: 28429102
Long-term safety and survival outcomes from the Scandinavian Breast Group 2004-1 randomized phase II trial of tailored dose-dense adjuvant chemotherapy for early breast cancer.
Alexios Matikas, Sara Margolin, +12 authors, Jonas Bergh.
Breast Cancer Res Treat, 2017 Dec 01; 168(2). PMID: 29190004    Free PMC article.
Comparable efficacy and less toxicity of pegylated liposomal doxorubicin versus epirubicin for neoadjuvant chemotherapy of breast cancer: a case-control study.
Minjun Dong, Liang Luo, +4 authors, Linbo Wang.
Onco Targets Ther, 2018 Aug 09; 11. PMID: 30087568    Free PMC article.
Cardio-oncology: protecting the heart from curative breast cancer treatment.
Jenica N Upshaw.
Gland Surg, 2018 Sep 04; 7(4). PMID: 30175052    Free PMC article.
Review.
The Impact of Adding Taxanes to Anthracyclines on Women with Breast Cancer Receiving Adjuvant Chemotherapy.
Erina Hilaj, Alketa Ymeri, Kleva P Shpati.
Cureus, 2020 Apr 08; 12(2). PMID: 32257663    Free PMC article.
Updated Survival Analysis after a Median Follow-up of 12 Years of an Anthracycline-Containing Adjuvant Prospective Multicentre, Randomised Phase III Trial on Dose-Dense Chemotherapy in Primary Node-Positive, High-Risk Breast Cancer Patients.
Mattea Reinisch, Oleg Gluz, +10 authors, Sherko Kümmel.
Breast Care (Basel), 2019 Jul 19; 14(3). PMID: 31316314    Free PMC article.
Clinical Characteristics and Outcome Trends of Adjuvant Anthracycline and Taxane Regimen for Early Stage Breast Cancer.
Ashok K Vaid, Aseem Khurana, +6 authors, Kush Gupta.
World J Oncol, 2020 Jun 05; 11(3). PMID: 32494317    Free PMC article.
Triple-negative breast cancer molecular subtyping and treatment progress.
Li Yin, Jiang-Jie Duan, Xiu-Wu Bian, Shi-Cang Yu.
Breast Cancer Res, 2020 Jun 11; 22(1). PMID: 32517735    Free PMC article.
Review.
Application of the ESMO-Magnitude of Clinical Benefit Scale (V.1.1) to the field of early breast cancer therapies.
Shani Paluch-Shimon, Nathan I Cherny, +4 authors, Fatima Cardoso.
ESMO Open, 2020 Sep 08; 5(5). PMID: 32893189    Free PMC article.
Gemcitabine as adjuvant chemotherapy in patients with high-risk early breast cancer-results from the randomized phase III SUCCESS-A trial.
Amelie de Gregorio, Lothar Häberle, +22 authors, Wolfgang Janni.
Breast Cancer Res, 2020 Oct 25; 22(1). PMID: 33097092    Free PMC article.